Relationship between non-alcoholic fatty liver disease and psoriasis: A novel Hepato-Dermal axis?

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Mantovani, Alessandro ^a   Gisondi, Paolo ^b   Lonardo, Amedeo ^c   Targher, Giovanni ^a  

^a Section of Endocrinology   (Italy)

^b University of Modena and Reggio Emilia and Azienda USL Modena ^*  (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Management; NAFLD; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Psoriasis

Indexed keywords

PIOGLITAZONE;

ADIPOSE TISSUE; ARTICLE; CYTOKINE PRODUCTION; DERMATITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; ELASTOGRAPHY; HUMAN; LIFESTYLE MODIFICATION; LIVER FIBROSIS; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PSORIASIS; SKIN BIOPSY; SYSTEMATIC REVIEW (TOPIC); UPREGULATION; ANIMAL; COMPLICATION; DISEASE MANAGEMENT; IMMUNOLOGY; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SKIN;

ANIMALS; DISEASE MANAGEMENT; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PSORIASIS; SKIN;

EID: 84957594998     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020217     Document Type: Article

References (63)

1. Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013, 133, 377-385. [CrossRef] [PubMed]
2. Griffiths, C.E.; Barker, J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370, 263-271. [CrossRef]
3. Gottlieb, A.B.; Chao, C.; Dann, F. Psoriasis comorbidities. J. Dermatol. Treat. 2008, 19, 5-21. [CrossRef] [PubMed]
4. Non-alcoholic fatty liver disease (NAFLD) Study Group, dedicated to the memory of Prof. Paola Loria; Lonardo, A.; Bellentani, S.; Argo, C.K.; Ballestri, S.; Byrne, C.D.; Caldwell, S.H.; Cortez-Pinto, H.; Grieco, A.; Machado, M.V.; et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis. 2015, 47, 997-1006.
5. Anstee, Q.M.; Targher, G.; Day, C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 330-344. [CrossRef] [PubMed]
6. Lonardo, A.; Ballestri, S.; Marchesini, G.; Angulo, P.; Loria, P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig. Liver Dis. 2015, 47, 181-190. [CrossRef] [PubMed]
7. Zhang, Y.; Zhang, T.; Zhang, C.; Tang, F.; Zhong, N.; Li, H.; Song, X.; Lin, H.; Liu, Y.; Xue, F. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open 2015, 5. [CrossRef] [PubMed]
8. Ballestri, S.; Zona, S.; Targher, G.; Romagnoli, D.; Baldelli, E.; Nascimbeni, F.; Roverato, A.; Guaraldi, G.; Lonardo, A. Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2015. [CrossRef] [PubMed]
9. Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol. 2015, 62, S47-S64. [CrossRef] [PubMed]
10. Ballestri, S.; Lonardo, A.; Bonapace, S.; Byrne, C.D.; Loria, P.; Targher, G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20, 1724-1745. [CrossRef] [PubMed]
11. Ogdie, A.; Gelfand, J.M. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr. Rheumatol. Rep. 2015, 17. [CrossRef] [PubMed]
12. Sommer, D.M.; Jenisch, S.; Suchan, M.; Christophers, E.; Weichenthal, M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006, 298, 321-328. [CrossRef] [PubMed]
13. Gisondi, P.; Tessari, G.; Conti, A.; Piaserico, S.; Schianchi, S.; Peserico, A.; Giannetti, A.; Girolomoni, G. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br. J. Dermatol. 2007, 157, 68-73. [CrossRef] [PubMed]
14. Chandra, A.; Ray, A.; Senapati, S.; Chatterjee, R. Genetic and epigenetic basis of psoriasis pathogenesis. Mol. Immunol. 2015, 64, 313-323. [CrossRef] [PubMed]
15. Lowes, M.A.; Suarez-Farinas, M.; Krueger, J.G. Immunology of psoriasis. Annu. Rev. Immunol. 2014, 32, 227-255. [CrossRef] [PubMed]
16. Durham, L.E.; Kirkham, B.W.; Taams, L.S. Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 2015, 17. [CrossRef] [PubMed]
17. Lonardo, A.; Loria, P.; Carulli, N. Concurrent non-alcoholic steatohepatitis ad psoriasis. Report of three cases from the POLI.ST.E.N.A. Study. Dig. Liver Dis. 2001, 33, 86-87. [CrossRef]
18. Matsumoto, T.; Suziki, N.; Watanabe, H.; Irie, M.; Iwata, K.; Anan, A.; Nakane, H.; Yoshikane, M.; Nishizawa, S.; Sohda, T.; et al. Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J. Gastroenterol. 2004, 39, 1102-1110. [CrossRef] [PubMed]
19. Gisondi, P.; Targher, G.; Zoppini, G.; Girolomoni, G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009, 51, 758-764. [CrossRef] [PubMed]
20. Miele, L.; Vallone, S.; Cefalo, C.; la Torre, G.; di Stasi, C.; Vecchio, F.M.; D’Agostino, M.; Gabrieli, M.L.; Vero, V.; Biolato, M.; et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009, 51, 778-786. [CrossRef] [PubMed]
21. Madanagobalane, S.; Anandan, S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: A study from South India. Australas. J. Dermatol. 2012, 53, 190-197. [CrossRef] [PubMed]
22. Van der Voort, E.A.; Koehler, E.M.; Dowlatshahi, E.A.; Hofman, A.; Stricker, B.H.; Janssen, H.L.; Schouten, J.N.; Nijsten, T. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J. Am. Acad. Dermatol. 2014, 70, 517-524. [CrossRef] [PubMed]
23. Van der Voort, E.A.; Koehler, E.M.; Nijsten, T.; Stricker, B.H.; Hofman, A.; Janssen, H.L.; Schouten, J.N.; Wakkee, M. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A cross-sectional analysis from the Rotterdam study. Acta Derm. Venereol. 2015. [CrossRef] [PubMed]
24. Gisondi, P.; Barba, E.; Girolomoni, G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2015, 30, 282-287. [CrossRef] [PubMed]
25. Abedini, R.; Salehi, M.; Lajevardi, V.; Beygi, S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin. Exp. Dermatol. 2015, 40, 722-727. [CrossRef] [PubMed]
26. Roberts, K.K.; Cochet, A.E.; Lamb, P.B.; Brown, P.J.; Battafarano, D.F.; Brunt, E.M.; Harrison, S.A. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment. Pharmacol. Ther. 2015, 41, 293-300. [CrossRef] [PubMed]
27. Candia, R.; Ruiz, A.; Torres-Robles, R.; Chávez-Tapia, N.; Méndez-Sánchez, N.; Arrese, M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 656-662. [CrossRef] [PubMed]
28. Birkenfeld, A.L.; Shulman, G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014, 59, 713-723. [CrossRef] [PubMed]
29. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Investig. 2006, 116, 1793-1801. [CrossRef] [PubMed]
30. Ucak, S.; Ekmekci, T.; Basat, O. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with types of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 517-522. [CrossRef] [PubMed]
31. Byrne, C.D.; Targher, G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: Implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1155-1161. [CrossRef] [PubMed]
32. Loria, P.; Carulli, L.; Bertolotti, M.; Lonardo, A. Endocrine and liver interaction: The role of endocrine pathways in NASH. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 236-247. [CrossRef] [PubMed]
33. Shulmann, G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 2014, 371, 1131-1141. [CrossRef] [PubMed]
34. Hunter, C.A.; Jones, S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015, 16, 448-457. [CrossRef] [PubMed]
35. Stefan, N.; Häring, H.U. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013, 9, 144-152. [CrossRef] [PubMed]
36. Targher, G.; Day, C.P.; Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363, 1341-1350.
37. Kulkarni, N.M.; Jaji, M.S.; Shetty, P.; Kurhe, Y.V.; Chaudhary, S.; Vijaykant, G.; Raghul, J.; Vishwakarma, S.L.; Rajesh, B.N.; Mookkan, J.; et al. A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation. Pharm. Biol. 2015, 53, 1110-1117. [CrossRef] [PubMed]
38. Nast, A.; Gisondi, P.; Ormerod, A.D.; Saiag, P.; Smith, C.; Spuls, P.I.; Arenberger, P.; Bachelez, H.; Barker, J.; Dauden, E.; et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris—Update 2015—Short version—EDF in cooperation with EADV and IPC. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 2277-2294. [CrossRef] [PubMed]
39. Gisondi, P.; Galvan, A.; Idolazzi, L.; Girolomoni, G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front. Med. 2015, 2. [CrossRef] [PubMed]
40. Kalb, R.E.; Strober, B.; Weinstein, G.; Lebwohl, M. Methotrexate and psoriasis: 2009 National psoriasis foundation consensus conference. J. Am. Acad. Dermatol. 2009, 60, 824-837. [CrossRef] [PubMed]
41. Hardwick, R.N.; Clarke, J.D.; Lake, A.D.; Canet, M.J.; Anumol, T.; Street, S.M.; Merrell, M.D.; Goedken, M.J.; Snyder, S.A.; Cherrington, N.J. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol. Sci. 2014, 142, 45-55. [CrossRef] [PubMed]
42. Rosenberg, P.; Urwitz, H.; Johannesson, A.; Ros, A.M.; Lindholm, J.; Kinnman, N.; Hultcrantz, R. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 2007, 46, 1111-1118. [CrossRef] [PubMed]
43. Gisondi, P.; Cazzaniga, S.; Chimenti, S.; Giannetti, A.; Maccarone, M.; Picardo, M.; Girolomoni, G.; Naldi, L. Psocare Study Group. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry. J. Eur. Acad. Dermatol. Venereol. 2013, 27, e30-e41. [CrossRef] [PubMed]
44. Neuvonen, P.J.; Niemi, M.; Backman, J.T. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin. Pharmacol. Ther. 2006, 80, 565-581. [CrossRef] [PubMed]
45. Dunn, L.K.; Gaar, L.R.; Yentzer, B.A.; O’Neill, J.L.; Feldman, S.R. Acitretin in dermatology: A review. J. Drugs Dermatol. 2011, 10, 772-782. [PubMed]
46. Martinez Abundis, E.; Reynoso-von, D.C.; Hernandez-Salazar, E.; Gonzalez-Ortiz, M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch. Dermatol. Res. 2007, 299, 461-465. [CrossRef] [PubMed]
47. Stanley, T.L.; Zanni, M.V.; Johnsen, S.; Rasheed, S.; Makimura, H.; Lee, H.; Khor, V.K.; Ahima, R.S.; Grinspoon, S.K. TNF-antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96, E146-E150. [CrossRef] [PubMed]
48. Solomon, D.H.; Massarotti, E.; Garg, R.; Liu, J.; Canning, C.; Schneeweiss, S. Association between disease-modifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305, 2525-2531. [CrossRef] [PubMed]
49. Lestre, S.; Diamantino, F.; Veloso, L.; Fidalgo, A.; Ferreira, A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: A retrospective cohort study. Eur. J. Dermatol. 2011, 21, 916-920. [PubMed]
50. Gisondi, P.; Conti, A.; Galdo, G.; Piaserico, S.; de Simone, C.; Girolomoni, G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study. Br. J. Dermatol. 2013, 168, 1124-1127. [CrossRef] [PubMed]
51. Tobon, G.J.; Cañas, C.; Jaller, J.J.; Restrepo, J.C.; Anaya, J.M. Serious liver disease induced by infliximab. Clin. Rheumatol. 2007, 26, 578-581. [CrossRef] [PubMed]
52. Tan, K.W.; Griffiths, C.E. Novel systemic therapies for the treatment of psoriasis. Expert. Opin. Pharmacother. 2016, 17, 79-92. [CrossRef] [PubMed]
53. Campanati, A.; Ganzetti, G.; di Sario, A.; Damiani, A.; Sandroni, L.; Rosa, L.; Benedetti, A.; Offidani, A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J. Gastroenterol. 2013, 48, 839-846. [CrossRef] [PubMed]
54. Feagins, L.A.; Flores, A.; Arriens, C.; Park, C.; Crook, T.; Reimold, A.; Brown, G. Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy. Eur. J. Gastroenterol. Hepatol. 2015, 27, 1154-1160. [CrossRef] [PubMed]
55. Del Giglio, M.; Gisondi, P.; Tessari, G.; Girolomoni, G. Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: A randomized, investigator-blinded study. Dermatology 2012, 224, 31-37. [CrossRef] [PubMed]
56. Jensen, P.; Zachariae, C.; Christensen, R.; Geiker, N.R.; Schaadt, B.K.; Stender, S.; Hansen, P.R.; Astrup, A.; Skov, L. Effect of weight loss on the severity of psoriasis: A randomized clinical study. JAMA Dermatol. 2013, 149, 795-801. [CrossRef] [PubMed]
57. Gisondi, P.; del Giglio, M.; di Francesco, V.; Zamboni, M.; Girolomoni, G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial. Am. J. Clin. Nutr. 2008, 88, 1242-1247. [PubMed]
58. Al-Mutairi, N.; Nour, T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin. Biol. Ther. 2014, 14, 749-756. [CrossRef] [PubMed]
59. Malhotra, A.; Shafiq, N.; Rajagopalan, S.; Dogra, S.; Malhotra, S. Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis. Evid. Based Med. 2012, 17, 171-176. [CrossRef] [PubMed]
60. Nascimbeni, F.; Pais, R.; Bellentani, S.; Day, C.P.; Ratziu, V.; Loria, P.; Lonardo, A. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013, 59, 859-871. [CrossRef] [PubMed]
61. Castera, L.; Vilgrain, V.; Angulo, P. Noninvasive evaluation of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 666-675. [CrossRef] [PubMed]
62. Ballestri, S.; Romagnoli, D.; Nascimbeni, F.; Francica, G.; Lonardo, A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 603-627. [CrossRef] [PubMed]
63. Lonardo, A.; Ballestri, S.; Targher, G.; Loria, P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 629-650. [CrossRef] [PubMed]